利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.037 秒)

    Nanodevices employing combinatorial artificial receptors
    1.
    发明申请
    Nanodevices employing combinatorial artificial receptors 审中-公开
    采用组合人造受体的纳米器件

    公开(公告)号：US20050136483A1

    公开(公告)日：2005-06-23

    申请号：US10934879

    申请日：2004-09-03

    申请人： Robert Carlson

    发明人： Robert Carlson

    IPC分类号： G01N33/53 ,  H01L21/00

    CPC分类号： B82Y5/00 ,  B82Y10/00

    摘要： The present invention includes nanodevices employing combinatorial artificial receptors and methods for making and using the same. In an embodiment the invention includes a method of adhering components together. In an embodiment, the invention includes a device including a first component adhered to a second component via a binding pair of artificial receptors. In an embodiment, the invention includes an agent delivery device having a capsule, and an active agent. In an embodiment, the invention can include a detection device having a magnetic particle and an artificial receptor disposed thereon. In an embodiment, the invention can include a detection device having a quantum dot and an artificial receptor disposed on the quantum dot. In an embodiment, the invention includes a detection device having first particles and second particles that aggregate in the present of a target ligand. In an embodiment, the invention includes a detection device having a cantilever and an artificial receptor disposed thereon. In an embodiment, the invention can include a detection device having a substrate and an artificial receptor disposed thereon. In an embodiment, the invention can include a device for selective removal of a target component including a substrate and an artificial receptor disposed thereon.

    摘要翻译： 本发明包括使用组合人造受体的纳米器件及其制造和使用方法。 在一个实施例中，本发明包括将部件粘合在一起的方法。 在一个实施方案中，本发明包括一种装置，其包括通过一对人造受体粘合到第二组分上的第一组分。 在一个实施方案中，本发明包括具有胶囊的药剂递送装置和活性剂。 在一个实施例中，本发明可以包括具有设置在其上的磁性颗粒和人造接收器的检测装置。 在一个实施例中，本发明可以包括具有量子点和设置在量子点上的人造受体的检测装置。 在一个实施方案中，本发明包括具有第一颗粒和在目标配体存在下聚集的第二颗粒的​​检测装置。 在一个实施例中，本发明包括具有悬臂和设置在其上的人造受体的检测装置。 在一个实施例中，本发明可以包括具有基底和设置在其上的人造受体的检测装置。 在一个实施例中，本发明可以包括用于选择性地去除包括衬底和设置在其上的人造接收器的目标部件的装置。

    Combinatorial artificial receptors including tether building blocks
    5.
    发明授权
    Combinatorial artificial receptors including tether building blocks 失效
    组合人造受体包括系链构建块

    公开(公告)号：US07504365B2

    公开(公告)日：2009-03-17

    申请号：US11219515

    申请日：2005-09-01

    申请人： Robert E. Carlson

    发明人： Robert E. Carlson

    IPC分类号： C40B50/00

    CPC分类号： G01N33/566 ,  G01N33/531 ,  G01N33/543 ,  G01N33/54353 ,  G01N33/6845 ,  G01N2500/00 ,  G01N2600/00

    摘要： The present invention relates to artificial receptors, arrays or microarrays of artificial receptors or candidate artificial receptors, methods of and compositions for making them, and methods of using them. Each artificial receptor includes a plurality of building block compounds. In an embodiment, at least one of the building blocks includes a tether moiety. The tether can provide spacing or distance between the recognition element and the support or scaffold to which the building block is immobilized. A tether moiety can have any of a variety of characteristics or properties including flexibility, rigidity or stiffness, ability to bond to another tether moiety, and the like.

    摘要翻译： 本发明涉及人造受体，人造受体或候选人受体的阵列或微阵列，其制备方法和组合物，以及使用它们的方法。 每个人造受体包括多个构建块化合物。 在一个实施方案中，至少一个构建块包括系链部分。 系链可以在识别元件和构建块固定到其上的支撑物或支架之间提供间隔或距离。 系链部分可以具有包括柔性，刚性或刚度，结合到另一系链部分的能力等各种特性或性质中的任何一种。

    Combinatorial artificial receptors including peptide building blocks
    6.
    发明申请
    Combinatorial artificial receptors including peptide building blocks 失效

    公开(公告)号：US20080182270A1

    公开(公告)日：2008-07-31

    申请号：US11223825

    申请日：2005-09-09

    申请人： Robert Carlson

    发明人： Robert Carlson

    IPC分类号： C40B40/10 ,  C07K1/02 ,  C07K14/705

    CPC分类号： C40B30/04 ,  C07K7/06 ,  C07K14/705 ,  Y02P20/55

    摘要： The present invention relates to artificial receptors, arrays or microarrays of artificial receptors or candidate artificial receptors, methods of and compositions for making them, and methods of using them. Each artificial receptor includes a plurality of building block compounds. In an embodiment, at least one of the building blocks includes or is a peptide moiety. In an embodiment, the building block can be a peptide or peptidomimetic of Formula A: R1R2N—R3—(R4)n—X—(R5)m—Y—C(O)—R6 in which R1 and R2 can independently be hydrogen or any suitable blocking or protecting group for an amino-terminal nitrogen of a peptide. Suitable blocking or protecting groups include those described in Green, T W; Wuts, PGM (1999), Protective Groups in Organic Synthesis Third Edition, Wiley-Interscience, New York, 779 pp. In an embodiment, R1 or R2 is hydrogen. In an embodiment, R1 is hydrogen and R2 is R7(O)C—, in which R7 can be lower (e.g., C1 to C6) alkyl, substituted lower (e.g., C1 to C6) alkyl, aryl, substituted aryl, or the like. In an embodiment, R1 is hydrogen and R2 is CH3(O)C—. In an embodiment, R1 and R2 are hydrogen. R3 can be absent or can be an amino acid, for example, an amino acid with a heteroatom on its side chain. Such amino acids include arginine, lysine, aspartic acid, glutamic acid, cysteine, glutamine, histidine, leucine, valine, methionine, phenylalanine, tyrosine, serine, threonine, and tryptophan. In an embodiment, R3 is arginine, lysine, aspartic acid, glutamic acid, cysteine, tyrosine, serine, or threonine. In an embodiment, R3 is arginine, lysine, aspartic acid, or glutamic acid. In an embodiment, R3 is arginine or lysine. In an embodiment, R3 is lysine. n can be 0, or n can be, for example, 1-25. In an embodiment, n=4-16. In an embodiment, n=3-6. In an embodiment, n=4. Each of the n R4 can independently be an amino acid. Suitable amino acids include any of the 20 naturally occurring amino acids. Each of the n R4 can independently be an amino acid with a small or unreactive side chain. In an embodiment, each of the n R4 is independently alanine, valine, proline, or glycine. In an embodiment, each of the n R4 is independently alanine or glycine. In an embodiment, each of the R4 is independently alanine or glycine and n=4. In an embodiment, each of the (R4)n is -Ala-Gly-Ala-Gly-. m can be 0, or m can be, for example, 1-6. In an embodiment, m=1-3. In an embodiment, m=1. In an embodiment, m=2. Each of the m R5 can independently be an amino acid. Suitable amino acids include any of the 20 naturally occurring amino acids. Each of the m R5 can independently be an amino acid with a small or unreactive side chain. In an embodiment, each of the m R5 is independently alanine, valine, proline, or glycine. In an embodiment, each of the m R5 is independently alanine or glycine. In an embodiment, R5 is alanine or glycine and m=1. In an embodiment, R5 is glycine and m=1. In an embodiment, R5 is alanine and m=1. In an embodiment, (R5)m has the formula —NR8—R9—CO— in which R8 can be H or an organic moiety and R9 can be an organic moiety. In certain embodiments, R8 is H, lower (e.g., C1 to C6) alkyl, substituted lower (e.g., C1 to C6) alkyl, aryl, substituted aryl, or the like; and R9 is lower (e.g., C1 to C6) alkyl, substituted lower (e.g., C1 to C6) alkyl, aryl, substituted aryl, or the like. In certain embodiments, R8 is H; and R9 is lower (e.g., C1 to C6) alkyl (e.g., branched lower alkyl). X and Y can independently be an amino acid, a dipeptide moiety (e.g., two amino acids linked by a peptide bond) or a tripeptide moiety (e.g., three amino acids linked by peptide bonds). Suitable amino acids include any of the 20 naturally occurring amino acids. Suitable dipeptide moieties include any two of the 20 naturally occurring amino acids. Suitable tripeptide moieties include any three of the 20 naturally occurring amino acids. In an embodiment, the amino acid or amino acids include or are arginine, glutamine, histidine, leucine, valine, methionine, phenylalanine, tyrosine, serine, threonine, or tryptophan. In an embodiment, the amino acid or amino acids include or are arginine, glutamine, histidine, methionine, threonine, tryptophan, aspartic acid, glutamic acid, leucine, phenylalanine, asparagine, isoleucine, serine, valine, tyrosine, or alanine. In an embodiment, X and Y are independently arginine, glutamine, histidine, methionine, threonine, tryptophan, aspartic acid, glutamic acid, leucine, phenylalanine, asparagine, isoleucine, serine, valine, tyrosine, or alanine. In an embodiment, X is arginine, glutamine, histidine, methionine, threonine, tryptophan, aspartic acid, glutamic acid, leucine, phenylalanine, asparagine, isoleucine, serine, valine, tyrosine, or alanine. In an embodiment, Y is arginine, glutamine, histidine, methionine, threonine, tryptophan, aspartic acid, glutamic acid, leucine, phenylalanine, asparagine, isoleucine, serine, valine, tyrosine, or alanine. In an embodiment, X and Y are independently arginine, glutamine, histidine, methionine, tyrosine, threonine, or tryptophan. In an embodiment, X is arginine, glutamine, histidine, methionine, tyrosine, threonine, or tryptophan. In an embodiment, Y is arginine, glutamine, histidine, methionine, tyrosine, threonine, or tryptophan. R6 can be hydrogen or any suitable blocking or protecting group for an carboxyl-terminal carboxyl group of a peptide. Suitable blocking or protecting groups include those described in Green, T W; Wuts, PGM (1999), Protective Groups in Organic Synthesis Third Edition, Wiley-Interscience, New York, 779 pp. In an embodiment, R6 is hydrogen. In an embodiment, R6 is —XR10, in which X is a heteroatom such as N, O, or S and R10 is lower (e.g., C1 to C6) alkyl, substituted lower (e.g., C1 to C6) alkyl, aryl, substituted aryl, or the like. In an embodiment, R6 is —NHCH3.